Aptamers Market: New Innovative Solution for Diverse Medical Applications
Aptamers are short single-stranded DNA or RNA (ssDNA or ssRNA) molecules that bind to a specific target protein, lipid, or nucleic acid molecules with high specificity. Aptamers can also be conjugated to drugs, working as drug-delivery systems. For example, aptamers have been conjugated with chemotherapy drugs to turn target and bind to only cancerous cells and leave healthy tissue untouched. Further, factors such as lesser chance of provoking undesired immune responses, high thermal stability, and cost-efficiency provide additional advantages to boost the demand for aptamers. These are produced through a technique called Systematic Evolution of Ligands by Exponential enrichment (SELEX), which is time-consuming and involves iterative steps. Thus, to overcome this disadvantage, Vivonics Inc. developed and patented a one-step rapid technique named Rapid Isolation of DNA Aptamers (RIDA) for the isolation of high affinity and high selectivity aptamers. These advancements are further expected to fuel adoption of aptamers.
Aptamers have attracted much attention recently for potential therapeutic and diagnostic purposes and have gained worldwide preference over antibodies owing to the former’s key benefits – lower cost, ability to not destroy neighboring cells, greater binding affinity, longer shelf life and, high specificity. These wide range of applications of aptamers have commanded medical industry to convey monetary clinical evidence and allow companies to significantly increase their influence to capture the untapped potential of aptamers, functioning as a key development opportunity that will propel the market growth.
The global aptamers market was valued at US$ 2,691.8 million in 2017 and is expected to witness a CAGR of 18.4% during the forecast period (2017 – 2025).
Figure 1. Global Aptamers Market Share, By Product Type (%)
Increasing number of applications will drive the overall aptamers market
Aptamer products can be used as biosensors, diagnostics, research agents or can be considered as a tool for biomarker or drug discovery. It can also be used for targeted therapeutics and bio-industrial applications. Use of in-vivo aptamer have a vast advantages by avoiding the majority of the bench testing, saving several years and approximately 35% of the R&D cost. It permits the natural selection of drug candidates in whole animal models, which reduces the false starts and required fewer animals needed for drug evaluation. All these factors have attracted a large number of companies to invest in this market. Moreover, growing incidence of life-threatening diseases such cancer has directed many companies to introduce new detection assays based on aptamer therapy which will help to booster the growth of the aptamer market. In March 2017, Aptamer Sciences, Inc. unveiled multiprotein biomarker assay by using this technology for the detection of lung cancer. However, stringent regulations related the use of aptamer and low awareness about these molecules in emerging economies such as Asia-Pacific and Middle East and Africa are some of the factors that may pose a challenge to the growth of the market.
Continuous innovations and collaborations among manufacturers and research institutes is a prominent factor to fuel the aptamers market
Continuous investments by biotechnological and pharmaceutical companies and introduction of next generation products are the major factors that boost the growth of the aptamer market. Growing number of academic research laboratories investigating the potential of aptamers and rising number of products under clinical investigation also increased the rate of market penetration and demand for aptamers across the globe. For Instance, Ophthotech Corporation’s Fovista, a chemically synthesized nucleic acid aptamer, is currently under clinical investigation.
North America hold the maximum share of aptamers market in 2016, owing to presence of major key players and strategic collaborations among them, followed by Europe. Asia Pacific is also expected to grow at a substantial rate due to increased investments in R&D and setting up of in-house manufacturing and R&D facilities.
Key vendors in the aptamers market are collaborating with each other or independent research organizations and institutes to retain or increase their market share. For example, in March 2014, Siva Therapeutics initiated a research collaboration with SomaLogic, Inc. to determine the ability of SomaLogic’s SOMAmer (Slow-off Rate Modified Aptamer) reagents to actively target gold nanorods to solid tumors. This is expected to create more opportunity for aptamer for a more diverse range of applications in the near future.
Aptamers is revolutionizing the healthcare industry by providing the affinity towards a desired target with high selectivity and specificity. This enable research scientists to gain interest towards the field of aptamers technology with increasing support from public-private organizations. Companies such as Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, and SomaLogic, Inc. are collaborating with each other or independent research organizations and institutes to speed-up the research activities for the treatment of a number of diseases in order to decrease the time to market (TTM).
Aptamers offer significant advantages related to protein therapeutics in terms of synthetic accessibility, size, and modification by medicinal chemistry which in turn aid in developing highly effective therapy. Continuous investment and development of novel aptamers by market players is propelling the market growth over the forecast period. Ophthotech is developing novel therapeutics Fovista and Zimura (an aptamer), used to treat eye diseases. Furthermore, advancements in Systemic Evolution of Ligands by Exponential Enrichment (SELEX) process to extract high-quality aptamers for a more diverse range of applications and government support in developed regions are anticipated to fuel utilization of these products, leading to market growth.
This report segments the global aptamers market on the basis of type, application, and end user. On the basis of type, the global aptamers market is classified into nucleic acid aptamers and peptide aptamers. Applications of aptamers include diagnostics, therapeutics, and research and development (R&D). Aptamers type is used for medical applications across pharmaceuticals and biotechnology companies, contract research organizations and academic and research institutions.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 90 market data tables and 40 figures on "Aptamers Market - Global forecast to 2025”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.